Autologous tumor cells engineered for immune system stimulation can target unique metabolic, genomic, and phenotypic characteristics of cancer cells.
Amanda Guth
Advertisement
Amanda Guth, DVM, PhD, is the chief scientific officer for PhotonPharma.
Articles by Amanda Guth
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Everything to Know About Cell and Gene Therapy in 2025
2
Biologics, Obesity, China Top Financial Trends Reshaping Pharma R&D in J.P. Morgan Report
3
Overcoming Funding Challenges and Maintaining Optimism in CGTs (Part 1)
4
CGT Innovations: The Three-Pronged Strategy for Industry Growth (Part 2)
5
